Meningococcal vaccines in China

References

• Dwilow R, Fanella S. Invasive meningococcal disease in the 21st century-an update for the clinician. Curr Neurol Neurosci Rep. 2015;15(3):2. doi:10.1007/s11910-015-0524-6.
   PubMed Web of Science ®Google Scholar
• Harrison OB, Claus H, Jiang Y, Bennett JS, Bratcher HB, Jolley KA, Corton C, Care R, Poolman JT, Zollinger WD. Description and nomenclature of Neisseria meningitidis capsule locus. Emerg Infect Dis. 2013;19(4):566–73. doi:10.3201/eid1904.111799.
   PubMed Web of Science ®Google Scholar
• Brooks R, Woods CW, Benjamin DK Jr., Rosenstein NE. Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994-2002. Clin Infect Dis. 2006;43(1):49–54. doi:10.1086/504804.
   PubMed Web of Science ®Google Scholar
• Laver JR, Hughes SE, Read RC. Neisserial molecular adaptations to the nasopharyngeal niche. Adv Microb Physiol. 2015;66:323–55.
   PubMed Web of Science ®Google Scholar
• Rouphael NG, Stephens DS. Neisseria meningitidis: biology, microbiology, and epidemiology. Methods Mol Biol. 2012;799:1–20.
   PubMedGoogle Scholar
• Jafri RZ, Ali A, Messonnier NE, Tevi-Benissan C, Durrheim D, Eskola J, Fermon F, Klugman KP, Ramsay M, Sow S. Global epidemiology of invasive meningococcal disease. Popul Health Metr. 2013;11(1):17. doi:10.1186/1478-7954-11-17.
   PubMed Web of Science ®Google Scholar
• Ding SQ. Group A meningococcal polysaccharide vaccine widely used in China. Bull Med Res. 1981;6:19.
   Google Scholar
• Xu M, Liang Z, Xu Y, Wang J. Chinese vaccine products go global: vaccine development and quality control. Expert Rev Vaccines. 2015;14(5):763–73. doi:10.1586/14760584.2015.1012503.
   PubMed Web of Science ®Google Scholar
• Li JH, Wu D, Yin ZD, Li YX. Analysis of epidemic characteristics for meningococcal meningitis in China during 2015-2017. Zhonghua yu fang yi xue za zhi [Chin J Prev Med]. 2019;53:159–63.
   PubMedGoogle Scholar
• Li J, Shao Z, Liu G, Bai X, Borrow R, Chen M, Guo Q, Han Y, Li Y, Taha M-K. Meningococcal disease and control in China: findings and updates from the Global Meningococcal Initiative (GMI). J Infect. 2018;76(5):429–37. doi:10.1016/j.jinf.2018.01.007.
   PubMed Web of Science ®Google Scholar
• Li J, Li Y, Shao Z, Li L, Yin Z, Xu L, Luo H. Prevalence of meningococcal meningitis in China from 2005 to 2010. Vaccine. 2015;33:1092–97.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wei D, Guo X, Han M, Yuan L, Kyaw MH. Burden of Neisseria meningitidis infections in China: a systematic review and meta-analysis. J Glob Health. 2016;6(2):20409. doi:10.7189/jogh.06.020409.
   PubMed Web of Science ®Google Scholar
• Ling J, Li Y, Luo H. Prevention and control of epidemic meningococcal meningitis. Disease surveillance. 2009;24:155–59.
   Google Scholar
• Shao Z, Xu L, Gao Y, Li M, Li Y, Yin Z, Liang X. Epidemiologic trend of serogroup switching of Neisseria meningitidis strains in China. Chin J Vaccin Immun. 2007;13:541–44.
   Google Scholar
• Shao Z, Li W, Ren J, Liang X, Xu L, Diao B, Li M, Lu M, Ren H, Cui Z. Identification of a new Neisseria meningitidis serogroup C clone from Anhui province, China. Lancet. 2006;367(9508):419–23. doi:10.1016/S0140-6736(06)68141-5.
   PubMed Web of Science ®Google Scholar
• Zhang X, Shao Z, Yang E, Xu L, Xu X, Li M, Ren J, Zhu Y, Yang F, Liang X. Molecular characterization of serogroup C Neisseria meningitidis isolated in China. J Med Microbiol. 2007;56(9):1224–29. doi:10.1099/jmm.0.47263-0.
   PubMed Web of Science ®Google Scholar
• Zhou H, Shan X, Sun X, Xu L, Gao Y, Li M, Shao Z. Clonal characteristics of invasive Neisseria meningitidis following initiation of an A + C vaccination program in China, 2005-2012. J Infect. 2015;70:37–43.
   PubMed Web of Science ®Google Scholar
• Zhu B, Xu Z, Du P, Xu L, Sun X, Gao Y, Shao Z. Sequence type 4821 clonal complex serogroup B Neisseria meningitidis in China, 1978-2013. Emerg Infect Dis. 2015;21(6):925–32. doi:10.3201/eid2106.140687.
   PubMed Web of Science ®Google Scholar
• Zhu BQ, Gao WY, Xu L, Gao Y, Shao ZJ. Molecular characteristics of serogroup B neisseria meningitidis, China. Zhonghua yu fang yi xue za zhi [Chin J Prev Med]. 2019;53:153–58.
   PubMedGoogle Scholar
• Guo Q, Mustapha MM, Chen M, Qu D, Zhang X, Chen M, Chen M, Wang M, Harrison LH. Evolution of sequence type 4821 clonal complex meningococcal strains in China from prequinolone to quinolone era, 1972-2013. Emerg Infect Dis. 2018;24(4):683–90. doi:10.3201/eid2404.171744.
   PubMed Web of Science ®Google Scholar
• He B, Jia Z, Zhou H, Wang Y, Jiang X, Ma H, Qian Z, Liu X, Shao Z, Chen S. CC4821 serogroup W meningococcal disease in China. Int J Infect Dis. 2014;29:113–14. doi:10.1016/j.ijid.2014.08.022.
   PubMed Web of Science ®Google Scholar
• Guo LC, Liu XC, Xu QY, Yiu YS Cai Y Jiang GQ Shao Z. Epidemiological analysis on serogroup Y neisseria meningitidis firstly isolated from patient in Tianjin. Zhonghua yu fang yi xue za zhi [Chin J Prev Med]. 2016;50:825–27.
   PubMedGoogle Scholar
• World Health Organization. Meningococcal vaccines: WHO position paper, November 2011. Releve epidemiologique hebdomadaire. 2011; 86:521–39.
   PubMedGoogle Scholar
• Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection–serum bactericidal antibody activity. Vaccine. 2005;23(17–18):2222–27. doi:10.1016/j.vaccine.2005.01.051.
   PubMed Web of Science ®Google Scholar
• Cui J, Cao L, Zheng J, Cao L, Duan M, Xiao Q. Reported coverage of vaccine in the national Immunizaiton program of China, 2015. Chin J Vaccin Immun. 2017;23:601–07.
   Google Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129(6):1307–26. doi:10.1084/jem.129.6.1307.
   PubMed Web of Science ®Google Scholar
• Gotschlich EC, Liu TY, Artenstein MS. Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides. J Exp Med. 1969;129(6):1349–65. doi:10.1084/jem.129.6.1349.
   PubMed Web of Science ®Google Scholar
• Gold R, Lepow ML, Goldschneider I, Draper TL, Gotschlich EC. Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J Clin Invest. 1975;56(6):1536–47. doi:10.1172/JCI108235.
   PubMed Web of Science ®Google Scholar
• Leach A, Twumasi PA, Kumah S, Banya WS, Jaffar S, Forrest BD, Granoff DM, LiButti DE, Carlone GM, Pais LB. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J Infect Dis. 1997;175(1):200–04. doi:10.1093/infdis/175.1.200.
   PubMed Web of Science ®Google Scholar
• Campagne G, Garba A, Fabre P, Schuchat A, Ryall R, Boulanger D, BYBEL M, CARLONE G, BRIANTAIS P, ANOFF B. Safety and immunogenicity of three doses of a Neisseria meningitidis A + C diphtheria conjugate vaccine in infants from Niger. Pediatr Infect Dis J. 2000;19(2):144–50. doi:10.1097/00006454-200002000-00013.
   PubMed Web of Science ®Google Scholar
• MacLennan JM, Shackley F, Heath PT, Deeks JJ, Flamank C, Herbert M, Griffiths H, Hatzmann E, Goilav C, Moxon ER. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: A randomized controlled trial. Jama. 2000;283(21):2795–801. doi:10.1001/jama.283.21.2795.
   PubMed Web of Science ®Google Scholar
• Wu C, Wang Y, Hang J, Xu J, Yuan W, Ma F, Tao H, Gong P. The efficacy and safety of A,C,W135,Y Meningococcal polysaccharide vaccines. Pract Prev Med. 2007;14:1768–70.
   Google Scholar
• Wahdan MH, Rizk F, el-Akkad AM, el-Ghoroury AA, Hablas R, Girgis NI, Amer A, Boctar W, Sippel JE, Gotschlich EC, et al. A controlled field trial of a serogroup A meningococcal polysaccharide vaccine. Bull World Health Organ. 1973;48:667–73.
   PubMed Web of Science ®Google Scholar
• Peltola H, Makela H, Kayhty H, Jousimies H, Herva E, Hallstrom K, Sivonen A, Renkonen O-V, Pettay O, Karanko V. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med. 1977;297(13):686–91. doi:10.1056/NEJM197709292971302.
   PubMed Web of Science ®Google Scholar
• Wei RT. Immunizing reactivity following vaccination with a purified fraction of Neisseria meningitidis and observations of effectiveness throughout 3 years. Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi. 1982;3:4–7.
   PubMedGoogle Scholar
• Ma Z. Observation on the epidemiologic efficacy for 9 years on epidemic meningococcal polysaccharide vaccine of group A by district immunization method. Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi. 1991;12:69–71.
   PubMedGoogle Scholar
• Yang J, Gong J, Liao Z. Observation on the injection reaction and immunogenicity of group A+C meningococcal polysaccharide vaccine. Applied Prev Med. 2006;12:338–42.
   Google Scholar
• Huang Z, QIan W, Yuan L, Chen Y, Cheng N, Zhou H, Li W, Yang M, Liu H. Preparation of group A+ C meningococcal polysaccharide conjugate vaccine. Chin J Biol. 2005;18:483–86.
   Google Scholar
• Peltola H, Safary A, Kayhty H, Karanko V, Andre FE. Evaluation of two tetravalent (ACYW135) meningococcal vaccines in infants and small children: a clinical study comparing immunogenicity of O-acetyl-negative and O-acetyl-positive group C polysaccharides. Pediatrics. 1985;76:91–96.
   PubMed Web of Science ®Google Scholar
• Vodopija I, Baklaic Z, Hauser P, Roelants P, Andre FE, Safary A. Reactivity and immunogenicity of bivalent (AC) and tetravalent (ACW135Y) meningococcal vaccines containing O-acetyl-negative or O-acetyl-positive group C polysaccharide. Infect Immun. 1983;42(2):599–604. doi:10.1128/IAI.42.2.599-604.1983.
   PubMed Web of Science ®Google Scholar
• Weintraub A. Immunology of bacterial polysaccharide antigens. Carbohydr Res. 2003;338(23):2539–47. doi:10.1016/j.carres.2003.07.008.
   PubMed Web of Science ®Google Scholar
• Lieberman JM, Chiu SS, Wong VK, Partidge S, Chang SJ, Chiu CY, Gheesling LL, Carlone GM, Ward JI. Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. A randomized controlled trial. Jama. 1996;275:1499–503.
   PubMed Web of Science ®Google Scholar
• Sow SO, Okoko BJ, Diallo A, Viviani S, Borrow R, Carlone G, Tapia M, Akinsola AK, Arduin P, Findlow H. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med. 2011;364(24):2293–304. doi:10.1056/NEJMoa1003812.
   PubMed Web of Science ®Google Scholar
• Chai Z, Li J, Shao Z, Li F, Diao L, Li L, Yin Z. Minutes of the meningococcal meningitis surveillance and immunization prevention seminar. Chin Prev Med. 2015;16:901–03.
   Google Scholar
• Tao H, Li Y, Wu C, Ye Q, Hong J, Xu J, Yuan W, Ma F. Study on safety and immunogenicity of group A/C meningococcal polysaccharide conjugate vaccine. Chin J Vaccin Immun. 2009;15:531–35.
   Google Scholar
• Zhou H, Wang JY, Tan Y, Lu HY, Wang M, Cai QC, Zhang HZ. Evaluation of safety of meningococcal group AC bivalent polysaccharide conjugate vaccine in children aged 5-24 months old. Zhonghua yu fang yi xue za zhi [Chin J Prev Med]. 2013;47:920–23.
   PubMedGoogle Scholar
• Fu C, Huang G, Cui M, Wang M. Post-marketing study on the safety of a meningococcal group A, C bivalent polysaccharide conjugate vaccine. Hum Vaccin Immunother. 2014;10(1):138–39. doi:10.4161/hv.26347.
   PubMed Web of Science ®Google Scholar
• Zheng J, Zhu X, Liu G, Du L. Immunogenicity and immune persistence of groups A&C meningococcal polysaccharide conjugate vaccine. Chin J Biol July. 2015;28:707–10.
   Google Scholar
• Wang YX, Tao H, Hu JL, Li JX, Dai WM, Sun JF, Liu P, Tang J, Liu W-Y, Zhu F-C. The immunogenicity and safety of a Hib-MenAC vaccine: a non-inferiority randomized, observer-blind trial in infants aged 3-5 months. Expert Rev Vaccines. 2017;16(5):515–24. doi:10.1080/14760584.2017.1303380.
   PubMed Web of Science ®Google Scholar
• Hu JL, Tao H, Li JX, Dai WM, Song B, Sun JF, Liu P, Tang J, Liu W-Y, Wang S-Y, et al. Safety and immunogenocity of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C-tetanus-toxoid conjugate vaccine in healthy Chinese children aged 6 months to 5 years old. Hum Vaccin Immunother. 2015;11(5):1120–28. doi:10.1080/21645515.2015.1033592.
   PubMed Web of Science ®Google Scholar
• Li J, Yang J, Liu X, Shi K, Yang H, Zheng W, Li S, Liu A, Zhang Z. Safety of post-marketing group A and C meningococcal conjugate and haemophilus type b conjugate combined vaccine among children aged 2-71 months. Chin J Vaccin Immun. 2016;22:578–81.
   Google Scholar
• Villena R, Safadi MAP, Valenzuela MT, Torres JP, Finn A, O’Ryan M. Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines. Hum Vaccin Immunother. 2018;14(5):1042–57. doi:10.1080/21645515.2018.1458175.
   PubMed Web of Science ®Google Scholar
• Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet. 1983;2(8346):355–57. doi:10.1016/S0140-6736(83)90340-9.
   PubMed Web of Science ®Google Scholar
• Holst J, Oster P, Arnold R, Tatley MV, Naess LM, Aaberge IS, Galloway Y, McNicholas A, O’Hallahan J, Rosenqvist E. Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future. Hum Vaccin Immunother. 2013;9(6):1241–53. doi:10.4161/hv.24129.
   PubMed Web of Science ®Google Scholar
• Rappuoli R, Pizza M, Masignani V, Vadivelu K. Meningococcal B vaccine (4CMenB): the journey from research to real world experience. Expert Rev Vaccines. 2018;17(12):1111–21. doi:10.1080/14760584.2018.1547637.
   PubMed Web of Science ®Google Scholar
• Flacco ME, Manzoli L, Rosso A, Marzuillo C, Bergamini M, Stefanati A, Cultrera R, Villari P, Ricciardi W, Ioannidis JPA. Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis. Lancet Infect Dis. 2018;18(4):461–72. doi:10.1016/S1473-3099(18)30048-3.
   PubMed Web of Science ®Google Scholar
• Parikh SR, Andrews NJ, Beebeejaun K, Campbell H, Ribeiro S, Ward C, White JM, Borrow R, Ramsay ME, Ladhani SN. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. Lancet. 2016;388(10061):2775–82. doi:10.1016/S0140-6736(16)31921-3.
   PubMed Web of Science ®Google Scholar
• Perez JL, Absalon J, Beeslaar J, Balmer P, Jansen KU, Jones TR, Harris S, York LJ, Jiang Q, Radley D. From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine. Expert Rev Vaccines. 2018;17(6):461–77. doi:10.1080/14760584.2018.1483726.
   PubMed Web of Science ®Google Scholar
• Marshall HS, Richmond PC, Beeslaar J, Jiang Q, Jansen KU, Garces-Sanchez M, Martinón-Torres F, Szenborn L, Wysocki J, Eiden J. Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2017;17(1):58–67. doi:10.1016/S1473-3099(16)30314-0.
   PubMed Web of Science ®Google Scholar
• Jia L, Yang R, Dong G. Study on improvement of national lot release regulations on biological products. Chin Pharm Affairs. 2010;24:523–30.
   Google Scholar
• National pharmacopoeia committee.The Chinese pharmacopoeia (2020 version) 3rd part. Beijing (China): Chinese Medical Science and Technology Press; 2020.
   Google Scholar
• Li Y, Zhao D, Li M, Li H, Liang L, Ye Q, Chen C. Trend analysis and quality evaluation for Group ACYW meningococcal polysaccharide vaccine in China. Chin J Biol. 2005;28:657–61.
   Google Scholar
• Cook MC, Bliu A, Kunkel JP. Quantitation of serogroups in multivalent polysaccharide-based meningococcal vaccines: optimisation of hydrolysis conditions and chromatographic methods. Vaccine. 2013;31(36):3702–11. doi:10.1016/j.vaccine.2013.05.098.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhu X, Ma Q, Cheng S, Zhao D, Wang S. Development and verification of immune rate turbidimetric method for quantitative determination of polysaccharide content in groups A and C meningococcus and Haemophilus influenzae type b combined vaccine. Chin J Biol. 2017;30:645–48.
   Google Scholar
• Wu J, Li J, Li Y, Shao Z, Li J, Zhu B, Wu D, Yao K, Liu G, Ye Q, et al. Chinese preventive medicine A. [Experts’ consensus on immunization with meningococcal vaccines in China]. Zhonghua yu fang yi xue za zhi [Chin J Prev Med]. 2019; 53:141–45.
   Google Scholar